Latest Breaking News On - Alliance for clinical trials in oncology - Page 1 : comparemela.com

Study Reveals Worse Clinical Outcomes in Breast Ca

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population Adverse events were consistent with known side effect.

Uproleselan Plus Chemotherapy Misses Phase 3 Trial OS End Point in R/R AML

Uproleselan plus chemotherapy did not achieve a statistically significant improvement in OS vs chemotherapy alone in patients with relapsed/refractory AML.

Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript

Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript April 30, 2024 Exelixis, Inc. misses on earnings expectations. Reported EPS is $0.17 EPS, expectations were $0.28. EXEL isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, ladies and gentlemen, and […]

Ongoing Research Drives Further Questions in Early-Stage Breast Cancer Management

Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer.